Procrit, Aranesp Reimbursement Adjusted; CMS Splits The Difference
The new payment formula for J&J's Procrit (epoetin alfa) and Amgen's Aranesp (darbepoetin alfa) under the Medicare Hospital Outpatient Prospective Payment System reflects the ratio of dosing used by Medicare providers in chemotherapy patients, CMS said
More from Archive
More from Pink Sheet
The EU is testing a groundbreaking “all-in-one” process for reviewing combined drug and diagnostic trials via a single application for coordinated assessment.
Madrigal Pharmaceuticals’ resmetirom could become the first approved treatment for non-cirrhotic metabolic dysfunction-associated steatohepatitis in the EU, if the European Medicines Agency issues a positive opinion for the drug later this week.
Center for Biologics Evaluation and Research Director Vinay Prasad said Commissioner Martin Makary wants to release previously inaccessible FDA documents, but previous commissioners have made the same pronouncements only to make little progress.